To test the impact of this variant on cancer risk and progression, we generated a humanized p53 knock-in (Hupki) mouse model, in which exons 4–9 of murine p53 were replaced by human p53 exons containing either WT or S47 p53. This evidence concerns the gene TP53 and cancer.